Literature DB >> 23044560

Assessment of the quality of life of pediatric patients at a center of excellence in dermatology in southern Brazil.

Magda Blessmann Weber1, Daniel Lorenzini, Clarissa Prieto Herman Reinehr, Bárbara Lovato.   

Abstract

BACKGROUND: Skin diseases cause negative impact on the emotional state, social relationships and daily activities, due to the stigma caused by the appearance of the lesions.
OBJECTIVE: This study aimed to assess the quality of life of pediatric patients with skin diseases attending a dermatology service, compare the scores obtained among the dermatoses found in the sample and associate them to the variables, in addition to observing how the skin disease specifically affects quality of life.
METHODS: Cross-sectional study, with patients between 5 and 16 years attending the Dermatology Service of the University of Health Sciences of Porto Alegre, Brazil, between July 2010 and February 2011. The data collection instruments were the Children's Dermatology Life Quality Index questionnaire and the AUEQI questionnaire.
RESULTS: A total of 161 patients were interviewed, with mean age of 9,66 years. The main dermatoses were atopic dermatitis (29.8%), warts (13%) and molluscum contagiosum (7.5%). Chronic diseases (73.9%) were the most prevalent. The overall mean Children's Dermatology Life Quality Index score was 5.01 for chronic dermatoses and 2.07 for acute illnesses, indicating a compromised quality of life among chronically ill patients. The comparison between the scores obtained with the AUEQI scale and the Children's Dermatology Life Quality Index scores indicates that the overall quality of life is less affected than the specific quality of life related to the dermatosis.
CONCLUSIONS: The data presented reinforce how important it is that the patients, their families and caregivers understand the symptoms, triggers and treatment of the skin disease in question. This information facilitates adherence to the treatment and justifies the conduct adopted by the dermatologist.

Entities:  

Mesh:

Year:  2012        PMID: 23044560     DOI: 10.1590/s0365-05962012000500004

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


  6 in total

1.  Translation, cross-cultural adaptation and validation of the vitiligo-specific health-related quality of life instrument (VitiQoL) into Brazilian Portuguese.

Authors:  Juliana Catucci Boza; Roopal V Kundu; Amanda Fabbrin; Roberta Horn; Natalia Giongo; Tania Ferreira Cestari
Journal:  An Bras Dermatol       Date:  2015-06-01       Impact factor: 1.896

Review 2.  Tuberous sclerosis complex: review based on new diagnostic criteria.

Authors:  Larissa Karine Leite Portocarrero; Klícia Novais Quental; Luciana Paula Samorano; Zilda Najjar Prado de Oliveira; Maria Cecília da Matta Rivitti-Machado
Journal:  An Bras Dermatol       Date:  2018-06       Impact factor: 1.896

3.  Psychiatric morbidity in children and adolescents with dermatological disorders.

Authors:  Dilşad Yıldız Miniksar; Özlem Özel Özcan; Hülya Cenk; Yelda Kapıcıoğlu; Ayşegül Polat
Journal:  Scand J Child Adolesc Psychiatr Psychol       Date:  2021-01-29

Review 4.  Atopic dermatitis and vitamin D: facts and controversies.

Authors:  Kleyton de Carvalho Mesquita; Ana Carolina de Souza Machado Igreja; Izelda Maria Carvalho Costa
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

5.  Quality of life in patients with vitiligo: a cross-sectional study based on Vitiligo Quality of Life index (VitiQoL).

Authors:  Kosar Hedayat; Mojgan Karbakhsh; Maryam Ghiasi; Azadeh Goodarzi; Yousef Fakour; Zahra Akbari; Afsaneh Ghayoumi; Narges Ghandi
Journal:  Health Qual Life Outcomes       Date:  2016-06-07       Impact factor: 3.186

6.  Pediatric dermatoses pattern at a Brazilian reference center.

Authors:  Isadora Zago Miotto; Vanessa Rolim Bessa; Luana Barreto de Almeida Vasconcelos; Luciana Paula Samorano; Maria Cecília Rivitti-Machado; Zilda Najjar Prado de Oliveira
Journal:  J Pediatr (Rio J)       Date:  2020-03-26       Impact factor: 2.990

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.